Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 3/20 | 1.00 |
| ▸ | BRS3 | P32247 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | MLN | P12872 | 1/20 | 0.98 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.98 |
| ▸ | F2 | P00734 | 8/20 | 0.47 |
| ▸ | PLAU | P00749 | 5/20 | 0.46 |
| ▸ | F10 | P00742 | 8/20 | 0.43 |
| ▸ | PLG | P00747 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349792 | 1.00 | SETD7 (1.00) | SETD7BRS3OPRK1MLNRADRA2B | |
| SCHEMBL29628952 | 1.00 | SETD7 (1.00) | SETD7BRS3OPRK1MLNRADRA2B | |
| Hydrochloric Acid SCHEMBL30314075 | 0.99 | SETD7 (1.00) | SETD7BRS3OPRK1MLNRADRA2B | |
| Hydrochloric Acid SCHEMBL29685937 | 0.99 | SETD7 (1.00) | SETD7BRS3OPRK1MLNRADRA2B | |
| SCHEMBL20472695 | 0.92 | SETD7 (0.85) | SETD7BRS3OPRK1MLNRADRA2B | |
| SCHEMBL20472697 | 0.92 | SETD7 (0.85) | SETD7BRS3OPRK1MLNRADRA2B | |
| SCHEMBL16487606 | 0.66 | MEN1 (0.70) | MEN1KMT2A | |
| SCHEMBL16487593 | 0.65 | MEN1 (0.69) | MEN1KMT2A | |
| SCHEMBL16487680 | 0.65 | MEN1 (0.69) | MEN1KMT2A | |
| SCHEMBL16487624 | 0.63 | THRB (0.72) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183751-A1 | HDR ENHANCERS | OXFORD GENETICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183751-A1 | HDR ENHANCERS | OXFORD GENETICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | SETD7 3948/4885BRS3 3576/4885OPRK1 1297/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | SETD7 4568/4885BRS3 4138/4885OPRK1 2814/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | SETD7 3834/4885BRS3 2621/4885OPRK1 1291/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | SETD7 4777/4885BRS3 4404/4885OPRK1 1783/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | SETD7 3280/4885BRS3 4337/4885OPRK1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.